Quanterix Corporation (QTRX)
NASDAQ: QTRXIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
QTRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $93.06M
- EPS (TTM)
- -$2.34
- Dividend yield
- None
- 52-week range
- 1.77 – 8.77
- Day range
- 1.78 – 2.03
- Volume / Avg
- 1.06M / 721.60K
- Beta
- —
- Shares outstanding
- 47.48M
52-week range
QTRX stock today
Shares of Quanterix (QTRX) finished lower on Nov 20 at $1.96, a drop of 3.45% or $0.07 per share, versus the S&P 500's 3.70% decline. Shares are 77.7% below their 52-week high of $8.77, set on Jan 9, 2026 and 11.0% above the 52-week low of $1.77, near the bottom of the past year's range. QTRX is down 69.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 70.6%.
Quanterix has posted a net loss over the last twelve months (EPS of -$2.34), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Quanterix
Company profileQuanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Mr. Everett V. Cunningham
- Headquarters
- Billerica, MA
- Employees
- 450
- IPO year
- 2017
- Website
- quanterix.com
Financial highlights
Full financialsIn fiscal 2025, Quanterix generated $138.9 million in revenue, up 1.1% from fiscal 2024, its 3rd consecutive year of revenue growth. Quanterix reported a net loss of $107.2 million, compared with a loss of $38.5 million a year earlier. Gross margin was 46.8% (down from 60.5%) and operating margin -90.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $138.90M | $137.42M | $122.37M | $105.52M | $110.56M |
| Growth | +1.07% | +12.30% | +15.96% | -4.55% | +27.99% |
| Net income | $-107.15M | $-38.53M | $-28.35M | $-99.57M | $-55.55M |
| EPS (diluted) | $-2.51 | $-1.00 | $-0.75 | $-2.69 | $-1.54 |
Analyst forecast
ForecastConsensus (3 analysts)
hold
Avg. price target
$3.33+69.90%
- Strong buy 0
- Buy 0
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.46 vs —
QTRX news
All QTRX news- Quanterix Corporation Announces Leadership Transition on November 18, 2026Nasdaq
- Quanterix Corp (QTRX) Q3 2026 Earnings Call TranscriptNasdaq
- Quanterix Corp Q3 Loss DecreasesNasdaq
- Quanterix Releases Financial Results for the Third Quarter of 2026Business Wire
- Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026Business Wire
- Tuesday Sector Laggards: Medical Instruments & Supplies, Advertising StocksNasdaqTXG, QTRX, FLNT, GRPN
Quanterix peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SEERSeer Inc. Class A | 1.36 | -1.81% | $75.91M | vs QTRX |
| HBIOHarvard Bioscience Inc. | 8.66 | -0.23% | $39.60M | vs QTRX |
| RPIDRapid Micro Biosystems Inc. Class A | 0.735 | -0.04% | $37.37M | vs QTRX |
| PRPOPrecipio Inc. | 17.35 | -6.17% | $31.11M | vs QTRX |
| EYPTEyePoint Inc. | 0.2342 | -11.36% | $26.65M | vs QTRX |
| CIRCCircle8 Group Inc. | 0.1361 | -12.25% | $15.99M | vs QTRX |
| BNGOBionano Genomics Inc. | 0.8222 | -7.11% | $11.50M | vs QTRX |
| ASTCAstrotech Corporation (DE) | 3.50 | -0.85% | $7.45M | vs QTRX |
Indexes, lists and sector
Quanterix stock FAQ
What is Quanterix's stock price today?
QTRX last traded at $1.96 as of Nov 20, 4:00 PM EST, down 3.45% on the day. Prices are delayed at least 15 minutes.
Who is Quanterix's CEO?
Mr. Everett V. Cunningham is the chief executive officer of Quanterix Corporation, which has about 450 employees.
What is the QTRX 52-week high?
The 52-week high for QTRX is $8.77 and the 52-week low is $1.77. The stock is currently 77.7% below its high.